Secukinumab shows significant efficacy in two patients with difficult-to-treat areas of psoriasis: a Greek experience.

Abstract

Psoriasis is one of the most frequently occurring chronic inflammatory skin diseases. There are some specialized regions of the body that are considered difficult to treat. Secukinumab is a human monoclonal immunoglobulin G antibody that blocks the interleukin 17A ligand and has been shown to be highly efficacious in treating moderate-to-severe psoriasis. We studied two Greek patients, one with scalp psoriasis and the other with palmoplantar psoriasis, both resistant to treatment. Patients were treated with secukinumab and efficacy and safety were recorded. The patient with severe, refractory palmoplantar psoriasis achieved complete clearance at the end of the 4-week treatment period with secukinumab. The patient with moderate to severe, chronic scalp psoriasis was successfully treated with secukinumab, obtaining complete clearance of symptoms and remission of disease after approximately 16 weeks. In both cases clinical response was maintained through week 52. Secukinumab has been shown to be highly efficacious in the treatment of psoriasis of specific anatomical sites with an acceptable safety profile.

• Authors: Eftychia Platsidaki, Nikolaos Kostopoulos, Ioannis Marnelakis, Pantelis Panagakis
• Journal: Dermatology online journal (Dermatol Online J) Vol. 24 Issue 3 (Mar 15 2018) ISSN: 1087-2108 [Electronic] United States
• PMID: 29634892 (Publication Type: Case Reports, Letter)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• secukinumab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Greece
• Humans
• Male
• Middle Aged
• Psoriasis (drug therapy, pathology)
• Remission Induction
• Severity of Illness Index
• Skin (pathology)